Topics

FDA Approves Ivosidenib for Frontline IDH1+ AML

13:50 EDT 2 May 2019 | OncLive

The FDA has approved a supplemental new drug application for ivosidenib as a single agent for the first-line treatment of adult patients with IDH1-mutant acute myeloid leukemia, as detected by an FDA-approved test, who are ≥75 years old or are ineligible to receive intensive chemotherapy.

Original Article: FDA Approves Ivosidenib for Frontline IDH1+ AML

NEXT ARTICLE

More From BioPortfolio on "FDA Approves Ivosidenib for Frontline IDH1+ AML"

Quick Search

Relevant Topic

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...